» Articles » PMID: 23635327

Construction of Escherichia Coli Strains with Chromosomally Integrated Expression Cassettes for the Synthesis of 2'-fucosyllactose

Overview
Publisher Biomed Central
Date 2013 May 3
PMID 23635327
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The trisaccharide 2'-fucosyllactose (2'-FL) is one of the most abundant oligosaccharides found in human milk. Due to its prebiotic and anti-infective properties, 2'-FL is discussed as nutritional additive for infant formula. Besides chemical synthesis and extraction from human milk, 2'-FL can be produced enzymatically in vitro and in vivo. The most promising approach for a large-scale formation of 2'-FL is the whole cell biosynthesis in Escherichia coli by intracellular synthesis of GDP-L-fucose and subsequent fucosylation of lactose with an appropriate α1,2-fucosyltransferase. Even though whole cell approaches have been demonstrated for the synthesis of 2'-FL, further improvements of the engineered E. coli host are required to increase product yields. Furthermore, an antibiotic-free method of whole cell synthesis of 2'-FL is desirable to simplify product purification and to avoid traces of antibiotics in a product with nutritional purpose.

Results: Here we report the construction of the first selection marker-free E. coli strain that produces 2'-FL from lactose and glycerol. To construct this strain, recombinant genes of the de novo synthesis pathway for GDP-L-fucose as well as the gene for the H. pylori fucosyltransferase futC were integrated into the chromosome of E. coli JM109 by using the λ-Red recombineering technique. Strains carrying additional copies of the futC gene and/or the gene fkp (from Bacteroides fragilis) for an additional salvage pathway for GDP-L-fucose production were used and shown to further improve production of 2'-FL in shake flask experiments. An increase of the intracellular GDP-L-fucose concentration by expression of fkp gene as well as an additional copy of the futC gene lead to an enhanced formation of 2'-FL. Using an improved production strain, feasibility of large scale 2'-FL production was demonstrated in an antibiotic-free fed-batch fermentation (13 l) with a final 2'-FL concentration of 20.28 ± 0.83 g l(-1) and a space-time-yield of 0.57 g l(-1) h(-1).

Conclusions: By chromosomal integration of recombinant genes, altering the copy number of these genes and analysis of 2'-FL and intracellular GDP-L-fucose levels, we were able to construct and improve the first selection marker-free E. coli strain which is capable to produce 2'-FL without the use of expression plasmids. Analysis of intracellular GDP-L-fucose levels identified the de novo synthesis pathway of GDP-L-fucose as one bottleneck in 2'-FL production. In antibiotic-free fed-batch fermentation with an improved strain, scale-up of 2'-FL could be demonstrated.

Citing Articles

Recent advances in the science of human milk oligosaccharides.

Urashima T, Ajisaka K, Ujihara T, Nakazaki E BBA Adv. 2025; 7:100136.

PMID: 39991261 PMC: 11847054. DOI: 10.1016/j.bbadva.2024.100136.


Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition.

Duman H, Bechelany M, Karav S Nutrients. 2025; 17(1.

PMID: 39796552 PMC: 11723173. DOI: 10.3390/nu17010118.


Metabolic engineering of Priestia megaterium for 2'-fucosyllactose production.

Park B, Yoon J, Lee J, Cho S, Choi Y, Cho B Microb Cell Fact. 2025; 24(1):2.

PMID: 39754105 PMC: 11699682. DOI: 10.1186/s12934-024-02620-w.


Guide RNA structure design enables combinatorial CRISPRa programs for biosynthetic profiling.

Fontana J, Sparkman-Yager D, Faulkner I, Cardiff R, Kiattisewee C, Walls A Nat Commun. 2024; 15(1):6341.

PMID: 39068154 PMC: 11283517. DOI: 10.1038/s41467-024-50528-1.


Efficient production of 2'-fucosyllactose from fructose through metabolically engineered recombinant Escherichia coli.

You R, Wang L, Hu M, Tao Y Microb Cell Fact. 2024; 23(1):38.

PMID: 38303005 PMC: 10835893. DOI: 10.1186/s12934-024-02312-5.


References
1.
Kunz C, Rudloff S, Baier W, Klein N, Strobel S . Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr. 2000; 20:699-722. DOI: 10.1146/annurev.nutr.20.1.699. View

2.
Ruiz-Palacios G, Cervantes L, Ramos P, Chavez-Munguia B, Newburg D . Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem. 2003; 278(16):14112-20. DOI: 10.1074/jbc.M207744200. View

3.
Coyne M, Reinap B, Lee M, Comstock L . Human symbionts use a host-like pathway for surface fucosylation. Science. 2005; 307(5716):1778-81. DOI: 10.1126/science.1106469. View

4.
Schwab C, Ganzle M . Lactic acid bacteria fermentation of human milk oligosaccharide components, human milk oligosaccharides and galactooligosaccharides. FEMS Microbiol Lett. 2010; 315(2):141-8. DOI: 10.1111/j.1574-6968.2010.02185.x. View

5.
Albermann C, Trachtmann N, Sprenger G . A simple and reliable method to conduct and monitor expression cassette integration into the Escherichia coli chromosome. Biotechnol J. 2009; 5(1):32-8. DOI: 10.1002/biot.200900193. View